Lunsumio Inj (Mosunetuzumab Vials) 30MG/30ML

Lunsumio Inj (Mosunetuzumab) 30mg/30ml vials is an injectable therapy for certain blood cancers. This monoclonal antibody targets CD20-positive cells to support immune response. Ideal for patients seeking targeted cancer treatments with clear handling guidance.

Strength

30MG/30ML

Pack Size

Storage

Ambient

Manufacturer / TM Owner

Genentech Inc USA

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Mosunetuzumab is used to treat relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma in adults. It is prescribed after at least two prior therapies have been tried. Patients often ask what is mosunetuzumab used for as it targets specific cancer cells in the blood.

Side Effects

Mosunetuzumab works by binding to CD20 on B-cells, helping the immune system recognize and attack cancer cells. Common effects include temporary changes in blood cell counts and immune response. Patients may experience fatigue or mild reactions at the injection site during treatment.

Precautions & Warnings

Store vials at ambient temperature away from light and moisture. Keep out of reach of children and pets. Avoid freezing or exposure to high heat. Handle vials carefully to prevent contamination or breakage. Always check the solution for particles or discoloration before use.

Avoid Interactions

Mosunetuzumab may interact with other immunosuppressants or live vaccines. Avoid alcohol and herbal supplements during treatment unless approved by a healthcare provider. CYP inhibitors or inducers may affect drug levels, so discuss all medications with your doctor. Monitor for signs of infection or immune reactions.

Frequently Asked Questions

Lunsumio Inj is used to treat certain types of relapsed or refractory blood cancers like follicular lymphoma and diffuse large B-cell lymphoma.

It is given as an intravenous infusion by a healthcare professional in a clinical setting.

Common effects include fatigue, low blood cell counts, and reactions at the injection site.

Availability varies by region and prescription requirements; consult a licensed pharmacy or healthcare provider.

No, it is a targeted therapy using monoclonal antibodies to treat specific cancer cells.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.